Market research
4MN.F Minerva Neurosciences, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.14
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US6033801068
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.14
About
About Minerva Neurosciences, Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4MN.F discussion.
5 years, 5 months ago
Minerva Neurosciences, Inc is currently in a long term downtrend where the price is trading 11.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.8.
Minerva Neurosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 75.5% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 49.5% to $-7M since the same quarter in the previous year.
Based on the above factors, Minerva Neurosciences, Inc gets an overall score of 3/5.